Circulating cathelicidin levels correlate with mucosal disease activity in ulcerative colitis, risk of intestinal stricture in Crohn's disease, and clinical prognosis in inflammatory bowel disease.
Circulating cathelicidin levels correlate with mucosal disease activity in ulcerative colitis, risk of intestinal stricture in Crohn's disease, and clinical prognosis in inflammatory bowel disease.
复制标题
DOI：
10.1186/s12876-017-0619-4
复制
发表时间：
2017-05-12
影响因子：
2.4
通讯作者：
Koon HW
中科院分区：
文献类型：
--
作者：
Tran DH;Wang J;Ha C;Ho W;Mattai SA;Oikonomopoulos A;Weiss G;Lacey P;Cheng M;Shieh C;Mussatto CC;Ho S;Hommes D;Koon HW
Cathelicidin （LL-37）是一种已知与多种自身免疫性疾病相关的抗菌肽。我们试图确定cathelicidin是否能准确反映IBD疾病的活动性。我们假设血清抗菌肽与IBD患者的粘膜疾病活动性、狭窄和临床预后相关。血清样本是从加州大学洛杉矶分校的两组患者中收集的。队列1包括50例对照组、23例UC和28例CD患者。队列2包括20名对照组，57名UC和67名CD患者。ELISA法检测LL-37水平。合并两个队列的数据以计算指示粘膜疾病活动性、狭窄的相对风险和预测疾病发展的优势比的准确性。血清抗菌肽水平与UC患者的部分Mayo评分和CD患者的Harvey-Bradshaw指数呈负相关。在中度或重度初始疾病活动性的IBD患者中，6-18个月后，初始LL-37水平高的患者恢复明显好于初始LL-37水平低的患者，提示LL-37水平高与预后良好相关。联合评估LL-37和CRP水平与UC患者Mayo内镜评分的相关性比单独评估CRP或单独评估LL-37更准确。低LL-37水平表明乳糜泻患者发生肠道狭窄的风险显著增加。联合评价LL-37和CRP可提示UC患者粘膜疾病的活动性。LL-37可以预测IBD患者未来的临床活动，并提示CD患者肠狭窄的风险。本文的在线版本（doi:10.1186/s12876-017-0619-4）包含补充材料，可供授权用户使用。
Cathelicidin (LL-37) is an antimicrobial peptide known to be associated with various autoimmune diseases. We attempt to determine if cathelicidin can accurately reflect IBD disease activity. We hypothesize that serum cathelicidin correlates with mucosal disease activity, stricture, and clinical prognosis of IBD patients. Serum samples were collected from two separate cohorts of patients at the University of California, Los Angeles. Cohort 1 consisted of 50 control, 23 UC, and 28 CD patients. Cohort 2 consisted of 20 control, 57 UC, and 67 CD patients. LL-37 levels were determined by ELISA. Data from both cohorts were combined for calculation of accuracies in indicating mucosal disease activity, relative risks of stricture, and odds ratios of predicting disease development. Serum cathelicidin levels were inversely correlated with Partial Mayo Scores of UC patients and Harvey-Bradshaw Indices of CD patients. Among IBD patients with moderate or severe initial disease activity, the patients with high initial LL-37 levels had significantly better recovery than the patients with low initial LL-37 levels after 6–18 months, suggesting that high LL-37 levels correlate with good prognosis. Co-evaluation of LL-37 and CRP levels was more accurate than CRP alone or LL-37 alone in the correlation with Mayo Endoscopic Score of UC patients. Low LL-37 levels indicated a significantly elevated risk of intestinal stricture in CD patients. Co-evaluation of LL-37 and CRP can indicate mucosal disease activity in UC patients. LL-37 can predict future clinical activity in IBD patients and indicate risk of intestinal stricture in CD patients. The online version of this article (doi:10.1186/s12876-017-0619-4) contains supplementary material, which is available to authorized users.